, Tracking Stock Market Picks
Enter Symbol:
Enzon Pharmaceuticals, Inc. (ENZN) [hlAlert]

down 87.64 %

Enzon Pharmaceuticals, Inc. (ENZN) rated Outperform with price target $14 by Oppenheimer

Posted on: Wednesday,  Sep 10, 2008  8:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) on 09/10/2008, when the stock price was $8.58. Since
then, Enzon Pharmaceuticals, Inc. has lost 87.65% as of 01/21/2016's recent price of $1.06.
If you would have followed this Oppenheimer's recommendation on ENZN, you would have lost 87.64% of your investment in 2689 days.

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets ABELCET, ONCASPAR, ADAGEN, and DEPOCYT in the United States. In addition, Enzon also receives royalties on sales of PEG-INTRON, marketed by Schering-Plough Corporation, and MACUGEN, marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a Customized Linker Technology PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon also utilizes contract manufacturing opportunities to broaden its revenue base and enhance its organizational productivity. Enzon complements its internal research and development efforts with strategic initiatives.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/10/2008 8:25 AM Buy
8.58 14.00
as of 12/24/2008
1 Week down  -1.16 %
1 Month down  -3.72 %
3 Months down  -1.81 %
1 YTD up  2.05 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy